@mbaliskhosanagp's Wegovy weight loss claims, fact-checked
Quick answer
Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist that mimics incretin hormones to slow gastric emptying and reduce appetite. The STEP clinical trial program demonstrated average weight loss of 14.9% over 68 weeks, though individual results vary significantly.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this video actually claim?
@mbaliskhosanagp shares her Wegovy journey, reporting a 6kg weight loss from 103kg to 97kg while adding a meal plan and cutting sugar. She credits the GLP-1 medication obtained from Lesedi Medical Centre for her "slowly melting" belly.
The creator presents a fairly typical Wegovy experience without making outrageous claims. She's transparent about combining the medication with dietary changes, which is exactly what the clinical trials tested.
Her weight loss timeline isn't specified, but the 5.8% reduction she's achieved so far falls within expected ranges for semaglutide treatment.
Does the science back up her results?
Her 6kg loss represents reasonable progress on Wegovy. The STEP 1 trial (Wilding et al., NEJM, 2021) found participants lost an average of 14.9% body weight over 68 weeks with 2.4mg semaglutide weekly.
At 5.8% weight loss, she's tracking below the trial average but within normal variation. Some participants in STEP 1 lost less than 5% of their body weight, while others exceeded 20%.
Her approach of combining Wegovy with meal planning mirrors the study protocol. All STEP trial participants received lifestyle counseling sessions every four weeks alongside medication.
The "belly melting" description, while unscientific, reflects how GLP-1 agonists can reduce visceral fat. However, spot reduction isn't how these medications work.
What did she get wrong?
The creator doesn't make significant medical errors, but her "belly melting" language suggests targeted fat loss. Semaglutide promotes overall weight reduction, not selective abdominal fat burning.
She also doesn't mention potential side effects. In STEP 1, 74.2% of participants experienced gastrointestinal events like nausea, diarrhea, or vomiting. This omission gives an incomplete picture of the Wegovy experience.
Her promotion of the specific medical center raises questions about potential compensation, though she doesn't disclose any business relationship.
What should you actually know about Wegovy?
Wegovy contains 2.4mg semaglutide weekly, starting with dose escalation from 0.25mg over 16 weeks. The medication costs around $1,300 monthly in the US without insurance coverage.
Real results take time. The STEP trials measured outcomes at 68 weeks, not weeks or months. Most participants didn't reach maximum weight loss until after one year of treatment.
Side effects are common and sometimes severe. In clinical trials, 7% of participants discontinued due to gastrointestinal problems. Rare but serious risks include pancreatitis and gallbladder disease.
The medication works best as part of comprehensive lifestyle changes, not as a standalone solution. When people stop taking semaglutide, they typically regain most of the lost weight within one year.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @mbaliskhosanagp's Wegovy weight loss claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
Wegovy (semaglutide 2.
FormBlends verdict
Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist that mimics incretin hormones to slow gastric emptying and reduce appetite. The STEP clinical trial program demonstrated average weight loss of 14.9% over 68 weeks, though individual results vary significantly.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist that mimics incretin hormones to slow gastric emptying and reduce appetite. The STEP clinical trial program demonstrated average weight loss of 14.9% over 68 weeks, though individual results vary significantly.
- STEP 1 trial participants lost an average of 14.9% body weight over 68 weeks on 2.4mg weekly semaglutide
- Individual results vary widely, with some people losing less than 5% and others exceeding 20% of body weight
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- STEP 1 trial participants lost an average of 14.9% body weight over 68 weeks on 2.4mg weekly semaglutide
- Individual results vary widely, with some people losing less than 5% and others exceeding 20% of body weight
- 74.2% of trial participants experienced gastrointestinal side effects like nausea, diarrhea, or vomiting
- Wegovy costs approximately $1,300 per month without insurance coverage in the United States
- Maximum weight loss typically occurs after one year of continuous treatment, not weeks or months
- Most people regain weight within one year of stopping semaglutide treatment
- Clinical trials combined medication with regular lifestyle counseling sessions for best results
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
MbaliwakaSkhosana · TikTok creator
48.1K views on this video
Wegovy injection update. My big belly is slowly melting away 🥺 My starting weight was 103kg and my current weight is 97kg. I recently started a meal plan and I’m also trying to cut off sugar. I g
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by MbaliwakaSkhosana, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.